How to buy Galecto stock (Galecto)

Galecto is a biotechnology business based in the US. Galecto shares (GLTO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.70 – a decrease of 7.48% over the previous week. Galecto employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Galecto Inc stock

Buy Galecto stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Galecto stock price (NASDAQ: GLTO)

Use our graph to track the performance of GLTO stocks over time.

Galecto shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$4.70
52-week range	$4.40 - $23.50
50-day moving average more info button	$6.40
200-day moving average more info button	$12.81
Wall St. target price	$10.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-19.11

Is it a good time to buy Galecto stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galecto price performance over time

Historical closes compared with the close of $4.7 from 2024-12-20

1 week (2024-12-13)	-7.48%
1 month (2024-11-22)	-16.37%
3 months (2024-09-20)	-64.56%
6 months (2024-06-21)	843.78%

1 year (2023-12-22)	640.16%
2 years (2022-12-22)	-84.96%
3 years (2021-12-22)	80.5
5 years (2019-12-18)	N/A

Galecto financials

Gross profit TTM	$0
Return on assets TTM	-34.29%
Return on equity TTM	-72.61%
Profit margin	0%
Book value	$16.70
Market Capitalization more info button	$6.3 million

TTM: trailing 12 months

Galecto share dividends

We're not expecting Galecto to pay a dividend over the next 12 months.

You may also wish to consider:

• Gilead Sciences (GILD.US) (3.4% forward annual dividend yield)

Have Galecto's shares ever split?

Galecto's shares were split on a 1:25 basis on 29 August 2024 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Galecto shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Galecto shares which in turn could have impacted Galecto's share price.

Galecto share price volatility

Over the last 12 months, Galecto's shares have ranged in value from as little as $4.4006 up to $23.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galecto's is 1.249. This would suggest that Galecto's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Galecto's beta into context you can compare it against those of similar companies.

• Gilead Sciences (GILD.US): 0.192

Galecto overview

Galecto, Inc. , a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. .

Frequently asked questions

null
What percentage of Galecto is owned by insiders or institutions?
Currently 3.459% of Galecto shares are held by insiders and 12.03% by institutions. How many people work for Galecto?
Latest data suggests 13 work at Galecto. When does the fiscal year end for Galecto?
Galecto's fiscal year ends in December. Where is Galecto based?
Galecto's address is: Ole Maaloes Vej 3, Copenhagen, Denmark, 2200 What is Galecto's ISIN number?
Galecto's international securities identification number is: US36322Q1076